Zortix matched this thesis to Biotech ETFs as one way for retail investors to get exposure. Not a recommendation.

China's biotech rise as a global competitor

The guest argued that China is systematically building capabilities in biotech, starting from early-stage clinical trials to eventually develop homegrown large pharma companies, challenging the traditional US/EU dominance.